The big pharma company will no longer progress emugrobart to late-stage trials in FSHD and SMA due to a lack of efficacy.

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Moderna (NASDAQ:MRNA) and the best and ...

Late-breaking AMETHYST Part A study results to be presented, showing safety and efficacy of litifilimab in cutaneous lupus erythematosus (CLE)Litifilimab was recently granted Breakthrough Therapy Desi ...

The company’s positioning frequently appears alongside broader movements.

Moderna CEO Stéphane Bancel’s total compensation remained remarkably stable last year at $19.9 million, even as the vaccines company navigated a “challenging regulatory and business environment.” ...

This biotech specializes in precision therapies for rare genetic diseases, with a pipeline targeting oncology and hematology indications.

In a report released today, Andrew Tsai from Jefferies maintained a Buy rating on Biogen, with a price target of $210.00. Tsai covers the Healthcare sector, focusing on stocks such as BridgeBio Pharma ...

Biogen (NasdaqGS:BIIB) reported one year results for salanersen in children with spinal muscular atrophy, showing clinical improvements and reduced neurodegeneration markers after once yearly dosing.

On March 11, 2026, Biogen Inc. announced that its Chief Legal Officer, Susan H. Alexander, will leave the company at the end of May 2026, marking a significant change in its senior executive ranks.

Biogen has outperformed its sector peers recently, and analysts remain moderately optimistic about the stock’s prospects.

Josh Brown, CEO of Ritholtz Wealth Management, made a pointed claim on CNBC’s Halftime Report this week about large-cap ...

Let’s dig into the relative performance of Biogen (NASDAQ:BIIB) and its peers as we unravel the now-completed Q4 therapeutics earnings season.